drugset / Trial / NCT07300839

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

NCT07300839

Phase 3 Active not recruiting 5240 enrolled BioNTech SE Pfizer · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect against COVID-19 (placebo).

Timeline

Start
2025-12-10
Primary completion
2026-07-31
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BNT162b2 Messenger RNA (mRNA)

Indications